I suppose anything is possible but I think Novartis is only in...

I suppose anything is possible but I think Novartis is only in it for ARDS and they may see a good match with CHF as well if good data comes out via Dr Perin (which it likely will). aGVHD would just be icing on top - but I would not expect they will just go with this indication alone (just too small a market by itself for a big pharma to get into bed with without the main meal so to say). I wouldn't think they would be able to exercise the aGVHD option without ARDS (unless the partnership agreement was renegotiated). This is just my opinion, I can not say for certain. This question came to my mind too, so any other thoughts appreciated.